Biodesix, Inc. Common Stock
BDSXBiodesix, Inc. is a molecular diagnostics company specializing in blood-based tests for lung disease, including lung cancer and infectious diseases. The company develops and commercializes liquid biopsy tests to aid in early detection, diagnosis, and treatment monitoring, leveraging advanced proteomic and genomic technologies to improve patient outcomes.
Company News
Biodesix reported Q4 2025 revenue of $28.8 million (41% increase) and full-year revenue of $88.5 million (24% increase), exceeding guidance. Lung Diagnostics revenue grew 47% in Q4 driven by increased test volumes and reimbursement expansion. The company affirmed expectations for positive Adjusted EBITDA in Q4 2025.
Biodesix's CFO Robin Cowie will host investor meetings at the Lake Street Capital Markets' 9th Annual Best Ideas Growth Conference in New York on September 11, 2025.
Biodesix will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, with CEO Scott Hutton and CFO Robin Cowie hosting a fireside chat and investor meetings in Boston, MA.
Biodesix will release its second quarter 2025 financial results on August 7, hosting a conference call and webcast to discuss financial performance and provide a business update.
Biodesix, a diagnostic solutions company, announced that new data from two studies will be presented at upcoming conferences. The studies highlight challenges in managing lung nodules and the potential of Biodesix's tests to guide clinical decision-making.
